Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer.
The VENTANA PD-L1 (SP263) Assay is approved for use with anti-programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) therapies in non-small cell lung cancer (NSCLC) and urothelial carcinoma. Here, we investigate inter-observer reliability of the SP263 assay, applied to PD-L1 scoring of tumor cells (TCs) in NSCLC. Six practicing European pulmonary pathologists independently scored the proportion of TCs expressing PD-L1 (TC score) from 200 archival, commercially sourced, formalin-fixed paraffin-embedded NSCLC resections stained using the SP263 assay. Agreement in scores was analyzed using the intra-class correlation coefficient (ICC) and concordance in patient classification using Fleiss' kappa. Results from 172 samples showed strong pair-wise correlations between pathologists (R2 >0.89) for TC scoring with an ICC of 0.96. Overall agreement was >90% for TC ≥1% and >94% for TC ≥25% and ≥50%. Fleiss' kappa showed substantial agreement for TC ≥1% and almost perfect agreement for TC ≥25% and ≥50%. Assessment of TC score in NSCLC was highly reproducible using the SP263 assay, building confidence in the accuracy of this assay in patient selection for anti-PD-1/PD-L1 therapy.